XFOR
X4 Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.27 / 10
Netural
Capital flows are robust (score 7.43/10), with overall inflow ratio at 0.4486 and negative trend flags across block, small, medium, large, and extra-large patterns. This liquidity cushion may support the stock in the short term. Analyst coverage is minimal—only one active analyst issues a Strong Buy rating with 100% historical win rate, but the broader consensus is neutral. The mismatch between positive fund flow and neutral analyst outlook underscores the need for vigilance; without stronger buy-side conviction or technical confirmation, upside momentum could stall.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-05
InstitutionStifel
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of XFOR?
- XFOR holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.27/10 (Netural).
